← All trials
NCT04329728
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2020
- Primary completion
- Jun 30, 2022
- Completion date
- Jun 30, 2023
- First posted
- Apr 1, 2020
- Last posted
- Apr 1, 2020
- Enrollment
- 144
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AVM Biotechnology LLCLead sponsor
- City of Hope National Medical CenterOverall official - principal investigator
- Gabrail Cancer CenterOverall official - principal investigator
- Innovative Clinical Research, Inc.Overall official - principal investigator
- Medpace, Inc.Collaborator
- University of Illinois at ChicagoOverall official - principal investigator
- The University of Texas, DallasOverall official - principal investigator
- City of Hope National Medical CenterOfficial
- Innovative Clinical Research, Inc.Official
- The University of Texas, DallasOfficial
- University of Illinois at ChicagoOfficial
- University of California, Los AngelesOfficial
- Gabrail Cancer CenterOfficial
- Nebraska Cancer SpecialistsOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.